默沙东(MRK)涨近1% OGSIVEO®获批用于治疗成人纤维瘤

金吾财讯
Aug 18, 2025

金吾财讯 | 默沙东(MRK)股价走高,截至发稿,涨0.87%,报84.94美元。消息面上,默克公司旗下医疗保健公司SpringWorks Therapeutics, Inc.今日宣布,欧盟委员会(EC)已批准口服γ-分泌酶抑制剂OGSIVEO® ( nirogacestat)作为单药疗法,用于治疗需要全身治疗的进展性纤维瘤成人患者。OGSIVEO是欧盟(EU)首个也是唯一一个获批用于治疗纤维瘤的疗法。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10